HYPAZ: An Open-label Investigation Into Hypertension Induced by Pazopanib Therapy.
Phase of Trial: Phase II
Latest Information Update: 04 Apr 2016
At a glance
- Drugs Pazopanib (Primary)
- Indications Advanced breast cancer; Cervical cancer; Gastrointestinal cancer; Glioblastoma; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Small cell lung cancer; Soft tissue sarcoma; Solid tumours
- Focus Adverse reactions
- Acronyms HYPAZ
- 20 Jul 2015 Planned End Date changed from 1 Sep 2018 to 1 Sep 2015 as per ClinicalTrials.gov record.
- 20 Jul 2015 Status changed from completed to discontinued as per ClinicalTrials.gov record..
- 18 Oct 2014 Status changed from recruiting to completed as reported by United Kingdom Clinical Research Network.